922 results on '"Pavletic, Steven Z."'
Search Results
2. Identification of Fibroinflammatory and Fibrotic Transcriptomic Subsets of Human Cutaneous Sclerotic Chronic Graft-Versus-Host Disease
3. Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions
4. Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA
5. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes
6. Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.
7. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
8. High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention
9. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials
10. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
11. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
12. The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease
13. Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients
14. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
15. Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease
16. Development and psychometric testing of a pediatric chronic graft-versus-host disease symptom scale: protocol for a two-phase, mixed methods study
17. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
18. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report
19. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report
20. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report
21. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease
22. Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI
23. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
24. Study protocol: Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH).
25. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia
26. Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions
27. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
28. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria
29. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies
30. W“H-Y” antigen/HLA complexes in chronic GVHD
31. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
32. Red cell distribution width as a new prognostic biomarker in refractory chronic graft-versus-host disease
33. Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis
34. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis
35. Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease
36. Introduction to a review series on emerging immunotherapies for hematologic diseases
37. Challenges in Conducting Studies in Chronic Graft-versus-Host Disease
38. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD
39. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients
40. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD
41. Forty years of hematopoietic stem cell transplantation in Croatia: First-World options and First-World science
42. Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease
43. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
44. Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease
45. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
46. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease
47. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen
48. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report
49. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report
50. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.